NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $1.80 -0.07 (-3.49%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CytomX Therapeutics Stock (NASDAQ:CTMX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CytomX Therapeutics alerts:Sign Up Key Stats Today's Range$1.81▼$2.0850-Day Range$1.86▼$2.9952-Week Range$0.40▼$3.10Volume8.75 million shsAverage Volume3.20 million shsMarket Capitalization$144.71 millionP/E Ratio3.21Dividend YieldN/APrice Target$5.75Consensus RatingBuy Company Overview CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Read More CytomX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreCTMX MarketRank™: CytomX Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 199th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCytomX Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about CytomX Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.05) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is 3.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.60.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is 3.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.16.Price to Book Value per Share RatioCytomX Therapeutics has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.61% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 6.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.74 Percentage of Shares Shorted29.61% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 6.61%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.04 News SentimentCytomX Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for CTMX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Stock News HeadlinesCytomX trial ongoing despite grade five event, says Oppenheimer2 hours ago | msn.comCytomX Therapeutics Provides Update on CX-2051 Phase 1 StudyAugust 13 at 8:00 AM | globenewswire.comWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.August 13 at 2:00 AM | Priority Gold (Ad)CytomX Therapeutics Earnings Call: Clinical Progress and Financial StrengthAugust 13 at 3:19 AM | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call TranscriptAugust 13 at 3:19 AM | msn.comHC Wainwright Issues Pessimistic Outlook for CTMX EarningsAugust 13 at 2:19 AM | americanbankingnews.comCytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comCytomX Therapeutics: Updated Outlook For Late 2025August 8, 2025 | seekingalpha.comSee More Headlines CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $1.03 at the start of the year. Since then, CTMX shares have increased by 76.2% and is now trading at $1.8150. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its quarterly earnings results on Monday, May, 12th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.18 by $0.09. The biotechnology company earned $50.92 million during the quarter, compared to analysts' expectations of $35.42 million. CytomX Therapeutics had a net margin of 34.04% and a trailing twelve-month return on equity of 158.70%. Read the conference call transcript. Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' top institutional investors include Franklin Resources Inc. (7.16%), Geode Capital Management LLC (2.16%), Acadian Asset Management LLC (1.93%) and Assenagon Asset Management S.A. (0.89%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Christopher Ogden, Lloyd A Rowland, Jeffrey B Landau, Carlos Campoy and Elaine V Jones. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), CymaBay Therapeutics (CBAY), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings5/12/2025Today8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTMX CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees170Year FoundedN/APrice Target and Rating Average Price Target for CytomX Therapeutics$5.75 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside+209.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.56 Trailing P/E Ratio3.32 Forward P/E RatioN/A P/E GrowthN/ANet Income$31.87 million Net Margins34.04% Pretax Margin34.18% Return on Equity158.70% Return on Assets36.04% Debt Debt-to-Equity RatioN/A Current Ratio4.20 Quick Ratio4.20 Sales & Book Value Annual Sales$141.10 million Price / Sales1.06 Cash Flow$0.29 per share Price / Cash Flow6.38 Book Value$1.49 per share Price / Book1.25Miscellaneous Outstanding Shares80,621,000Free Float75,300,000Market Cap$149.96 million OptionableOptionable Beta2.13 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CTMX) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.